Skip to content
10-Q

Quarterly Report

BIOSCIENCE NEUTRACEUTICALS, INC.

0001640334-19-002231

← back to feed
Filed
Nov 12, 2019 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2019 · Oct 8, 2019 8.04M sh
Operating Cash Flow Q3 2019 · Sep 30, 2019 −$32.25K
Operating Cash Flow Q3 2019 · Sep 30, 2018 −$31.63K
Short Term Debt Q3 2019 · Sep 30, 2019 $3.96K
Short Term Debt Q3 2019 · Dec 31, 2018 $3.96K
Stockholders Equity Q3 2019 · Sep 30, 2019 −$227.09K
Stockholders Equity Q3 2019 · Jun 30, 2019 −$217.82K
Stockholders Equity Q3 2019 · Mar 31, 2019 −$202.51K
Stockholders Equity Q3 2019 · Dec 31, 2018 −$185.32K
Stockholders Equity Q3 2019 · Sep 30, 2018 −$179.28K
Stockholders Equity Q3 2019 · Jun 30, 2018 −$168.29K
Stockholders Equity Q3 2019 · Mar 31, 2018 −$141.68K
Stockholders Equity Q3 2019 · Dec 31, 2017 −$129.54K
Current Liabilities Q3 2019 · Sep 30, 2019 $223.13K
Current Liabilities Q3 2019 · Dec 31, 2018 $187.36K
Total Liabilities Q3 2019 · Sep 30, 2019 $227.09K
Total Liabilities Q3 2019 · Dec 31, 2018 $191.32K
Sga Expense Q3 2019 · Sep 30, 2019 $788
Sga Expense Q3 2019 · Sep 30, 2019 $1.17K
Net Income Q3 2019 · Sep 30, 2019 −$9.27K
Net Income Q3 2019 · Sep 30, 2019 −$471.68K
Net Income Q3 2019 · Sep 30, 2018 −$10.98K
Net Income Q3 2019 · Sep 30, 2018 −$49.73K
Operating Income Q3 2019 · Sep 30, 2019 −$3.99K
Operating Income Q3 2019 · Sep 30, 2019 −$471.68K
Operating Income restated Q3 2019 · Sep 30, 2018 −$2.95K
Operating Income restated Q3 2019 · Sep 30, 2018 −$22.96K
Current Assets Q3 2019 · Dec 31, 2018 $6K
Total Assets Q3 2019 · Dec 31, 2018 $6K
Cash And Equivalents Q3 2019 · Sep 30, 2018 $1.09K
Cash And Equivalents Q3 2019 · Dec 31, 2017 $1.49K